$21.02
+0.02 (+0.10%)
Open$21.47
Previous Close$21.00
Day High$22.35
Day Low$21.01
52W High$54.29
52W Low$9.00
Volume—
Avg Volume5.4K
Market Cap76.31M
P/E Ratio—
EPS$-17.09
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+29.8% upside
Current
$21.02
$21.02
Target
$27.28
$27.28
$18.57
$27.28 avg
$35.01
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.22M | 12.16M | 13.52M |
| Net Income | 1.67M | 1.59M | 1.78M |
| Profit Margin | 13.7% | 13.1% | 13.2% |
| EBITDA | 2.79M | 3.00M | 3.51M |
| Free Cash Flow | 1.30M | 1.27M | 1.44M |
| Rev Growth | +12.4% | +20.7% | +15.7% |
| Debt/Equity | 0.63 | 0.63 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |